Gil Van Bokkelen Net Worth

The estimated Net Worth of Bokkelen Gil Van is at least $1.92 Milión dollars as of 12 August 2019. Gil Van owns over 20,000 units of Athersys Inc stock worth over $162,468 and over the last 17 years he sold ATHX stock worth over $161,025. In addition, he makes $1,596,650 as Chairman of the Board a Chief Executive Officer at Athersys Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Gil Bokkelen ATHX stock SEC Form 4 insiders trading

Gil has made over 23 trades of the Athersys Inc stock since 2007, according to the Form 4 filled with the SEC. Most recently he exercised 20,000 units of ATHX stock worth $25,600 on 12 August 2019.

The largest trade he's ever made was buying 22,500 units of Athersys Inc stock on 28 November 2008 worth over $9,900. On average, Gil trades about 4,859 units every 85 days since 2007. As of 12 August 2019 he still owns at least 1,595,949 units of Athersys Inc stock.

You can see the complete history of Gil Van stock trades at the bottom of the page.

Gil Van Bokkelen biography

Dr. Gil Van Bokkelen Ph.D. serves as Chairman of the Board, Chief Executive Officer of the Company. Dr. Van Bokkelen has served as our Chief Executive Officer and Chairman since August 2000. Dr. Van Bokkelen co-founded Athersys in 1995 and has served as Chief Executive Officer and Director since the Company’s founding. Prior to May 2006, he also served as the Company’s President. Dr. Van Bokkelen is also the Chairman of the Board of Governors for the National Center for Regenerative Medicine. He serves on the board of the Alliance for Regenerative Medicine (and served as chairman from 2010 through 2012), a Washington D.C. based consortium of companies, patient advocacy groups, disease foundations, and clinical and research institutions that are committed to the advancement of the field of regenerative medicine, and he served ex officio from 2013 to 2014. He has served on a number of other boards, including the Biotechnology Innovation Organization’s board of directors (from 2001 to 2004, and from 2008 to present). He received his Ph.D. in Genetics from Stanford University School of Medicine, his B.A. in Economics from the University of California at Berkeley, and his B.A. in Molecular Biology from the University of California at Berkeley. Dr. Van Bokkelen brings to the Board leadership, extensive business, operating, financial and scientific experience, and tremendous knowledge of our Company and the biotechnology industry. Dr. Van Bokkelen also brings his broad strategic vision for our Company to the Board of Directors and his service as the Chairman and Chief Executive Officer of Athersys creates a critical link between management and the Board, enabling the Board to perform its oversight function with the benefit of management’s perspectives on the business. In addition, having the Chief Executive Officer, and Dr. Van Bokkelen, in particular, on our Board of Directors provides our Company with ethical, decisive and effective leadership.

What is the salary of Gil Bokkelen?

As the Chairman of the Board a Chief Executive Officer of Athersys Inc, the total compensation of Gil Bokkelen at Athersys Inc is $1,596,650. There are no executives at Athersys Inc getting paid more.

How old is Gil Bokkelen?

Gil Bokkelen is 59, he's been the Chairman of the Board a Chief Executive Officer of Athersys Inc since 2000. There are 4 older and 9 younger executives at Athersys Inc. The oldest executive at Athersys Inc is Lorin Randall, 76, who is the Independent Director.

Insiders trading at Athersys Inc

Over the last 17 years, insiders at Athersys Inc have traded over $3,715,462 worth of Athersys Inc stock and bought 2,242,389 units worth $3,620,264 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Michael B Sheffery a Jordan Davis. On average, Athersys Inc executives and independent directors trade stock every 43 days with the average trade being worth of $3,231. The most recent stock trade was executed by Daniel A. Camardo on 22 November 2022, trading 100,000 units of ATHX stock currently worth $55,000.

What does Athersys Inc do?

athersys is a clinical stage biopharmaceutical company with a growing pipeline of highly differentiated, potential best in class therapeutics to treat significant and life-threatening diseases. we are engaged in the discovery and development of innovative new medicines designed to extend and enhance the quality of human life. through the application of our proprietary technologies, we have established a pipeline of therapeutic product development programs in multiple disease areas. this pipeline includes both stem cell therapy and pharmaceuticals.

Complete history of Gil Van stock trades at Athersys Inc

Athersys Inc executives and stock owners

Athersys Inc executives and other stock owners filed with the SEC include:

• Gil Van Bokkelen,
  Chairman of the Board, Chief Executive Officer
• John Harrington,
  Executive Vice President, Chief Scientific Officer, Director
• William Lehmann,
  President, Chief Operating Officer
• Laura Campbell,
  Senior Vice President - Finance
• Ivor Macleod CPA, M.B.A.,
  Chief Financial Officer & Principal Accounting Officer
• Dr. John J. Harrington,
  Co-Founder, Chief Scientific Officer, Exec. VP & Director
• William B. J. Lehmann Jr., M.B.A., J.D., MBA,
  Pres, COO, Sec. & Interim CEO
• Lorin Randall,
  Independent Director
• Jack Wyszomierski,
  Independent Director
• Ismail Kola,
  Independent Director
• Jane Wasman,
  Director
• Baiju Shah,
  Director
• Katherine Kalin,
  Director
• Hardy Kagimoto,
  Director
• Maia Hansen,
  Senior Vice President - Operations, Supply Chain
• Ivor Macleod,
  Chief Financial Officer
• Dr. Eric Jenkins M.D.,
  Sr. Medical Director & Head of Clinical Operations
• Maia Hansen M.B.A., M.S.,
  Sr. VP and Head of Operations & Supply Chain
• Rakesh Ramachandran,
  Head of Information Technology & Communications and VP
• Dr. Robert Mays Ph.D.,
  VP of Regenerative Medicine & Head of Neuroscience Programs
• Dr. Manal Morsy M.D., PH.D.,
  Sr. VP & Head of Global Regulatory Affairs
• Alison O'Sullivan M.B.A.,
  Sr. Director of HR
• Karen Hunady M.S.,
  Director of Corp. Communications & Investor Relations
• Jordan Davis,
  Director
• Lee Babiss,
  Director
• Neema Mayhugh,
  Director
• Joseph Patrick Nolan,
  Director
• K.K. Healios,
  
• Tadahisa Kagimoto,
  Director
• Robert J Deans,
  Sr. Vice President
• Kenneth Traub,
  Director
• Advisors Llc Orbi Med Capit...,
  
• George M Jr Milne,
  Director
• Floyd D Md Loop,
  Director
• Advisors Llcisaly Samuel D ...,
  
• Michael B Sheffery,
  Director
• William C Mulligan,
  Director
• Daniel A. Camardo,
  CEO